A Phase I, Randomized, Double-Blind Clinical Trial of the HIV gp120/NefTat/AS02A Vaccine Candidate in Subjects With Well-Controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART).
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2011
At a glance
- Drugs AS02; HIV vaccine
- Indications HIV-1 infections
- Focus Therapeutic Use
- 23 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 24 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.